MDXG Q3 2021 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$666M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M-1.9% YoY

Gross Profit

$53M83.9% margin

Operating Income

-$1M-1.7% margin

Net Income

-$2M-3.7% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-7.5%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$181M

Total Liabilities

$94M

Stockholders' Equity

$87M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$64M	-1.9%
Gross Profit	$53M	$54M	-2.0%
Operating Income	-$1M	-$10M	+88.9%
Net Income	-$2M	-$19M	+88.0%

Revenue Segments

Health Care

$62M50%

Advanced Wound Care, Tissue And Other

$56M45%

Advanced Wound Care, Umbilical Cord-Derived

$6M5%

Section 351

$500,0000%

Product and Service, Other

$303,0000%